Company / Accounts Receivable
Pfizer Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$11.9B
FY2025
5-year range
$11.0B / $11.9B
FY2021-FY2025
Trend
+3.6%
vs FY2024
Sector context
#4 of 113
Health Care
What the data says
Among 113 Health Care companies, Pfizer is in the top 4% for accounts receivable. Accounts Receivable has increased for 3 consecutive years, from $11.0B in FY2022 to $11.9B in FY2025.
Based on SEC 10-K filings.
$11.9B in FY2025 with a 5-year CAGR of +8.5%. Top quartile in the Health Care sector.
Improved from $11.2B to $11.9B over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +2.7%
- 5-Year CAGR
- +8.5%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 113This company $11.9B Sector average $1.1B
▼
+943.9% above sector average
Key checks
Key Insights
- Pfizer's accounts receivable has grown for 3 consecutive years.
- 5-year CAGR of +8.5%, indicating consistent growth.
- In FY2025, accounts receivable increased 3.6% year-over-year.
- Ranks #4 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.09 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.9B | +3.6% |
| FY2024 | $11.5B | +2.6% |
| FY2023 | $11.2B | +2.1% |
| FY2022 | $11.0B | -4.6% |
| FY2021 | $11.5B | +45.1% |
| FY2020 | $7.9B | +16.8% |
| FY2019 | $6.8B | -17.8% |
| FY2018 | $8.2B | +0.2% |
| FY2017 | $8.2B | -0.0% |
| FY2016 | $8.2B | +0.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026